Q4 2021 Results
Company overview
Pharmaceuticals
Participants
Financial performance
Novartis pipeline in Phase 2
Oncology
Code
AAA601
Name
LutatheraⓇ
ABL001 ScemblixⓇ
BLZ945
BLZ945
Mechanism
Indication(s)
Radioligand therapy target SSTR GEPNET, pediatrics
BCR-ABL inhibitor
CSF-1R inhibitor
Chronic myeloid leukemia, 2L, pediatrics
Solid tumors
HGG/LGG, pediatrics
Non-small cell lung cancer (Combo)
DRB436 Tafinlar® + Mekinist®
INC280
TabrectaⓇ
INC424 JakaviⓇ
JDQ443 JDQ443
BRAF inhibitor + MEK inhibitor
Met inhibitor
JAK1/2 inhibitor
KRAS inhibitor
LNP023 iptacopan
LXH254 LXH254
CFB inhibitor
CRAF inhibitor
MBG453
sabatolimab
NIR178 NIR178, spartalizumab
NIS793 NIS793
PKC412 Rydapt
SEG101 Adakveo®
TNO155 TNO155
Immunology
Myelofibrosis (combo)
NSCLC (combo)
Oncology
Innovation: Pipeline overview
Financial review
Conclusion
Appendix
Innovation: Clinical trials
29 lead indications
Ophthalmology
Name
Code
CPK850 CPK850
LKA651 LKA651
SAF312 libvatrep
UNR844 UNR844
Respiratory & Allergy
Mechanism
RLBP1 AAV
EPO inhibitor
TRPV1 antagonist
Reduction of disulfide bonds
Indication(s)
Retinitis pigmentosa
Diabetic retinopathy
Chronic ocular surface pain
Presbyopia
Acute GVHD,
pediatrics
Chronic GVHD,
pediatrics
Code
CMK389
CSJ117
Name
CMK389
Mechanism
IL-18 inhibitor
CSJ117
QBW251
icenticaftor
QMF149 Atectura®
TSLP inhibitor
CFTR potentiator
Combo
TIM3 antagonist
Ad2AR inhibitor, PD1 inhibitor
TGFB1 inhibitor
Multi-targeted kinase inhibitor
P-selectin inhibitor
SHP2 inhibitor
Autoimmune cytopenias
Melanoma (combo)
Unfit acute myeloid leukaemia
Acute myeloid leukaemia, maintenance
Cancers
Colorectal cancer (Combos)
Acute myeloid leukemia, pediatrics
Sickle cell anaemia with crisis, pediatrics
Solid tumors (single agent)
Lead indication
Indication(s)
Pulmonary sarcoidosis
Asthma
Bronchiectasis
Chronic obstructive pulmonary disease
Chronic obstructive pulmonary disease
Asthma, pediatrics
Cardiovascular, Renal, Metabolism
Code
Name
CFZ533 iscalimab
HSY244 HSY244
Mechanism
CD40 inhibitor
CFB inhibitor
Indication(s)
Lupus nephritis Type 1 diabetes mellitus
Atrial fibrillation
Membranous nephropathy
Code
Hidradenitis suppurativa
Code
Name
ADPT02 ADPT02
AIN457 Cosentyx®
CFZ533 iscalimab
CMK389 CMK389
Mechanism
Indication(s)
Non-alcoholic steatohepatitis (Combos)
IL17A inhibitor
Lichen planus
CD40 inhibitor
Sjögren's
Liver Tx
IL-18 inhibitor
Atopic dermatitis
DFV890 DFV890
NLRP3 inhibitor
Osteoarthritis
LNP023 iptacopan
Neuroscience
Name
ADPT06 ADPT06
BLZ945 BLZ945
DLX3132 DLX313
LMI070 branaplam
MIJ821 MIJ821
Mechanism
CSF-1R inhibitor
Alpha-synuclein Inhibitor
mRNA splicing modulator
NR2B negative allosteric
modulator
Indication(s)
Cognitive impairment
Amyotrophic lateral sclerosis
Parkinson's disease
Huntington's disease
Acute depression
LJN452
LNA043 LNA043
LOU064
remibrutinib
LRX712 LRX712
tropifexor +licogliflozin
FXR agonist
Familial cold auto-inflammatory syndrome
Non-alcoholic steatohepatitis (Combos)
ANGPTL3 agonist
BTK inhibitor
Knee osteoarthritis
Sjögren's
Osteoarthritis (combos)
Global Health
Osteoarthritis
LYS006
LYS006
Anti-inflammatory
Acne
MAS825 MAS825
NLRC4-GOF indications
Colitis ulcerative Hidradenitis suppurativa
Hidradenitis suppurativa
MHV370 MHV370
VAY736 ianalumab
Sjögren's
BAFF-R inhibitor
Sjögren's
Autoimmune hepatitis
LXE408
Systemic lupus erythematosus
SKO136
Code Name
KAE609 cipargamin
KAF156 ganaplacide
LXE408
ensovibep
Mechanism
PfATP4 inhibitor
Indication(s)
Malaria, severe Malaria, uncomplicated
Malaria, uncomplicated
Proteasome inhibitor
Visceral leishmaniasis
Multi-specific DARPin
Corona virus infection
1. Clinical hold lifted. 2. UCB0599.
61 Investor Relations | Q4 2021 Results
U NOVARTIS | Reimagining MedicineView entire presentation